Novavax, Inc. (NVAX)

174.84 +16.74 (+10.59%) At close: 4:00PM EST

Novavax, Inc.

21 Firstfield Road
Gaithersburg, MD 20878
United States
240 268 2000
http://www.novavax.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 792

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Stanley Charles Erck	Pres, CEO & Director	1.45M	N/A	1948
Mr. John A. Herrmann III	Exec. VP, Chief Legal Officer & Corp. Sec.	865.02k	N/A	1966
Dr. Gregory M. Glenn	Pres of R&D	1.06M	N/A	1954
Mr. John Joseph Trizzino	Exec. VP, Chief Bus. & Commercial Officer & Treasurer	881.5k	N/A	1960
Mr. Gregory F. Covino	Exec. VP & CFO	N/A	N/A	1966
Mr. Richard P. Crowley	Exec. VP & COO	N/A	N/A	1957
Mr. Biegie Lee	Sr. VP & Chief Information Officer	N/A	N/A	N/A
Ms. Silvia Taylor M.B.A., MBA	Sr. VP of Investor Relations & Corp. Affairs	N/A	N/A	N/A
Ms. Erika S. Trahan	Associate Director of Investor & PR	N/A	N/A	N/A
Mr. Sven Andreasson M.B.A.	Sr. VP of Corp. Devel.	N/A	N/A	1952

Amounts are as of 31 December 2019, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. In addition, the company develops vaccine candidates for the protection against middle east respiratory syndrome, as well as that is in preclinical work associated with severe acute respiratory syndrome; and ebola virus glycoprotein vaccine candidate, as well as COVID-19 vaccine for variant strain. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

Corporate governance

Novavax, Inc.’s ISS governance QualityScore as of 3 December 2020 is 6. The pillar scores are Audit: 6; Board: 5; Shareholder rights: 7; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.